Drug intelligence / Profile preview

bucillamine + methotrexate

Development stage: Unknown
Lead developer: Revive Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy of two disease-modifying antirheumatic drugs (DMARDs) used primarily for the treatment of rheumatoid arthritis. This combination has shown significantly higher clinical efficacy than either drug alone in clinical trials, particularly for early rheumatoid arthritis. The combination therapy demonstrates better ACR20 response rates and reduced joint damage progression compared to monotherapy with either agent.

Targets

DHFR (Dihydrofolate reductase)

Beyond the preview

Go deeper on bucillamine + methotrexate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bucillamine + methotrexate.

Explore the full profile